We are live on
!
Find out more
SM
Sabby Management Portfolio holdings
AUM
$111M
1-Year Est. Return
74.4%
This Fund
S&P 500
This Quarter
Est. Return
-6.02%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.53B
AUM Growth
-$325M
(-18%)
Cap. Flow
+$93M
Cap. Flow
% of AUM
6.09%
Top 10 Holdings %
Top 10 Hldgs %
65.86%
Holding
300
New
43
Increased
68
Reduced
83
Closed
84
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$95.6M |
| 2 |
TSRO
TESARO, Inc.
TSRO
|
+$7.45M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$5.41M |
| 4 |
Microbot Medical
MBOT
|
+$4.73M |
| 5 |
United Therapeutics
UTHR
|
+$4.46M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$6.09M |
| 2 |
Ionis Pharmaceuticals
IONS
|
+$5.39M |
| 3 |
MTFB
Motif Bio plc ADRs
MTFB
|
+$4.6M |
| 4 |
OTIC
Otonomy, Inc.
OTIC
|
+$3.19M |
| 5 |
Palisade Bio
PALI
|
+$2.63M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 86.02% |
| 2 | Healthcare | 13.32% |
| 3 | Materials | 0.27% |
| 4 | Technology | 0.24% |
| 5 | Financials | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.88B
| $3.41M | 0.22% |
442
-3,946
| -90% | -$284K |
|
|
SAGE
52
CALL
DELISTED
Sage Therapeutics
SAGE
| $3.38M | 0.22% |
424
+136
| +47% | +$9.83K |
|
53
PUT
Insmed
INSM
$26.2B
| $3.26M | 0.21% |
1,899
-1,162
| -38% | -$19.8K |
|
|
KITE
54
DELISTED
Kite Pharma, Inc.
KITE
| $3.25M | 0.21% |
+31,384
| New | +$2.56M |
|
55
CALL
Pacira BioSciences
PCRX
$971M
| $3.24M | 0.21% |
+679
| New | +$31.5K |
|
|
56
PUT
Pacira BioSciences
PCRX
$971M
| $3.23M | 0.21% |
+678
| New | +$31.5K |
|
57
CALL
Gilead Sciences
GILD
$179B
| $3.21M | 0.21% |
454
-7,832
| -95% | -$521K |
|
|
MBAI
58
MBody AI Ltd. Ordinary Share
MBAI
$8.67M
| $2.72M | 0.18% |
845
+696
| +467% | +$2.37M |
|
|
FOLD
59
PUT
DELISTED
Amicus Therapeutics
FOLD
| $2.7M | 0.18% |
2,682
+441
| +20% | +$3.55K |
|
60
Wave Life Sciences
WVE
$873M
| $2.64M | 0.17% |
+141,700
| New | +$3.05M |
|
|
ZGNX
61
CALL
DELISTED
Zogenix, Inc.
ZGNX
| $2.52M | 0.16% |
1,735
+919
| +113% | +$11.6K |
|
|
BLRX
62
BioLineRX
BLRX
$12.1M
| $2.51M | 0.16% |
4,915
-321
| -6% | -$165K |
|
|
ASXC
63
DELISTED
Asensus Surgical, Inc.
ASXC
| $2.46M | 0.16% |
+266,103
| New | +$2.53M |
|
64
Outlook Therapeutics
OTLK
$154M
| $2.37M | 0.16% |
14,786
+796
| +6% | +$225K |
|
|
SGEN
65
CALL
DELISTED
Seagen Inc. Common Stock
SGEN
| $2.27M | 0.15% |
438
+196
| +81% | +$12.5K |
|
|
KDMN
66
DELISTED
Kadmon Holdings, Inc.
KDMN
| $2.11M | 0.14% |
+542,869
| New | +$1.54M |
|
|
ARRY
67
PUT
DELISTED
Array Biopharma Inc
ARRY
| $2.09M | 0.14% |
2,500
| – | – |
|
|
IMMP
68
Immutep
IMMP
$49.7M
| $1.99M | 0.13% |
+962,835
| New | +$2.33M |
|
69
Ocugen
OCGN
$339M
| $1.95M | 0.13% |
18,073
-184
| -1% | -$18.8K |
|
|
SRRA
70
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $1.95M | 0.13% |
41,562
-2,095
| -5% | -$107K |
|
|
GBT
71
CALL
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $1.83M | 0.12% |
670
+265
| +65% | +$7.88K |
|
|
72
Microbot Medical
MBOT
$96.7M
| $1.82M | 0.12% |
+85,690
| New | +$4.73M |
|
73
CorMedix
CRMD
$604M
| $1.82M | 0.12% |
+848,783
| New | +$2.9M |
|
74
CALL
PTC Therapeutics
PTCT
$5.46B
| $1.79M | 0.12% |
977
+824
| +539% | +$11.1K |
|
|
CNSY
75
Cerenome
CNSY
$16.6M
| $1.79M | 0.12% |
9
+2
| +29% | +$404K |
|
Similar funds
IWA
BFA
WPWM
BCM
ZS
KC
FI
CIM
Sabby Management's Q2 2017 Portfolio in Review
As of Q2 2017, Sabby Management held 300 positions worth $1.53B, down 18% from $1.85B the previous quarter. Its ten largest holdings account for 66% of the portfolio.
Sabby Management deployed $93M of net new capital in Q2 2017, opening 43 new positions and adding to 68 existing holdings. Its largest new stake was TESARO, Inc.: 51,426 shares worth $7.19M.
By sector, the portfolio is most concentrated in Miscellaneous at 86% of assets, down from 93% a quarter earlier, followed by Healthcare and Materials.
On the sell side, the largest reduction was Otonomy, Inc., an estimated $3.19M trimmed.
- Sabby Management's largest Q2 2017 buy was TESARO, Inc.: 51,426 shares worth $7.19M.
- Sabby Management added most to Bristol-Myers Squibb in Q2 2017, an estimated $95.6M increase.
- Sabby Management's biggest Q2 2017 reduction was Otonomy, Inc., cutting an estimated $3.19M.
- Sabby Management fully exited Amgen in Q2 2017, selling an estimated $6.09M.
- Sabby Management's ten largest holdings make up 66% of its $1.53B portfolio in Q2 2017.
- Sabby Management opened 43 new positions and closed 84 in Q2 2017.
- Sabby Management's portfolio value fell 18% quarter-over-quarter to $1.53B.
Based on Sabby Management's 13F filing for Q2 2017, filed 14 Aug 2017.